Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015790 | 1.00 | LMNA (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL215095 | 1.00 | LMNA (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL540415 | 1.00 | LMNA (0.41) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Ammonia Solution, Strong SCHEMBL4744785 | 0.98 | LMNA (0.39) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL14808559 | 0.98 | LMNA (0.39) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Ammonia Solution, Strong SCHEMBL2015573 | 0.98 | LMNA (0.39) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Ammonia Solution, Strong SCHEMBL482689 | 0.98 | LMNA (0.39) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL7068618 | 0.94 | LMNA (0.37) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL7144047 | 0.94 | LMNA (0.37) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL3864585 | 0.94 | LMNA (0.37) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063535-A | Modified nucleoside containing amino derivative structure, oligonucleotide compound and synthesis method | 北京安龙生物医药有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-116789679-A | Cycloicaritin 5-glycosylation derivative and preparation method and application thereof | 遵义医科大学 | 2023-09-22 | — | — | CN | claimed |
| US-9200026-B2 | Antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | claimed |
| US-20130101588-A1 | NOVEL GLYCOSYLATED PEPTIDE TARGET IN NEOPLASTIC CELLS | PATRYS LIMITED (AU) | 2013-04-25 | — | — | US | claimed |
| JP-2011518784-A | — | — | 2011-06-30 | — | — | JP | claimed |
| EP-2274425-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | Alnylam Pharmaceuticals Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| US-7799763-B2 | Muscle-strengthening drugs and anti-inflammatory drugs | DAICHO KIKAKU INCORPORATED COMPANY (JP) | 2010-09-21 | — | — | US | claimed |
| WO-2009126933-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| EP-2101813-A2 | NOVEL GLYCOSYLATED PEPTIDE TARGET IN NEOPLASTIC CELLS | PATRYS LIMITED (AU) | 2009-09-23 | — | — | EP | claimed |
| WO-2009023773-A9 | GALACTOKINASE INHIBITORS | UNIV MIAMI (US) | 2009-07-30 | — | — | WO | claimed |
| US-20080199475-A1 | NOVEL GLYCOSYLATED PEPTIDE TARGET IN NEOPLASTIC CELLS | PATRYS LIMITED (AU) | 2008-08-21 | — | — | US | claimed |
| US-20070129316-A1 | MUSCLE-STRENGTHENING DRUGS AND ANTI-INFLAMMATORY DRUGS | DAICHO KIKAKU INCORPORATED COMPANY (JP) | 2007-06-07 | — | — | US | claimed |
| EP-0956000-A4 | SYNTHESIS OF GLYCOPHOSPHOLIPID AND PEPTIDE-PHOSPHOLIPID CONJUGATES AND USES THEREOF | UNIV EMORY (US) | 2004-06-09 | — | — | EP | claimed |
| US-6071532-A | SYNTHETIC VACCINES; IMMUNOLOGY; MEDICAL DIAGNOSIS | EMORY UNIVERSITY (US) | 2000-06-06 | — | — | US | claimed |
| EP-0956000-A1 | SYNTHESIS OF GLYCOPHOSPHOLIPID AND PEPTIDE-PHOSPHOLIPID CONJUGATES AND USES THEREOF | EMORY UNIVERSITY (US) | 1999-11-17 | — | — | EP | claimed |
| EP-0946581-A1 | THERAPEUTIC COMPOUNDS | Oxford GlycoSciences (UK) Limited (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998028318-A1 | THERAPEUTIC COMPOUNDS | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 1998-07-02 | — | — | WO | claimed |
| WO-1998016198-A1 | SYNTHESIS OF GLYCOPHOSPHOLIPID AND PEPTIDE-PHOSPHOLIPID CONJUGATES AND USES THEREOF | EMORY UNIVERSITY (US) | 1998-04-23 | — | — | WO | claimed |
| EP-0762884-A1 | MODULATORS OF PNEUMOCOCCAL ADHESION TO CELLULAR TARGETS INVOLVING THE PLATELET ACTIVATING FACTOR RECEPTOR, AND USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1997-03-19 | — | — | EP | claimed |
| WO-1995035112-A2 | MODULATORS OF PNEUMOCOCCAL ADHESION TO CELLULAR TARGETS INVOLVING THE PLATELET ACTIVATING FACTOR RECEPTOR, AND USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1995-12-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129316-A1 | MUSCLE-STRENGTHENING DRUGS AND ANTI-INFLAMMATORY DRUGS | CYP27A1, ACHE, MYLK | LMNA 829/4885L3MBTL1 4393/4885PDE4A 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.